164 related articles for article (PubMed ID: 15046685)
1. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence.
Lorenzo GD; Bianco R; Tortora G; Ciardiello F
Clin Prostate Cancer; 2003 Jun; 2(1):50-7. PubMed ID: 15046685
[TBL] [Abstract][Full Text] [Related]
2. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu receptor in prostate cancer development and progression to androgen independence.
Di Lorenzo G; Autorino R; De Laurentiis M; Cindolo L; D'Armiento M; Bianco AR; De Placido S
Tumori; 2004; 90(2):163-70. PubMed ID: 15237576
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
6. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
[TBL] [Abstract][Full Text] [Related]
7. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
[TBL] [Abstract][Full Text] [Related]
8. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
9. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
10. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
Formento P; Hannoun-Levi JM; Fischel JL; Magné N; Etienne-Grimaldi MC; Milano G
Eur J Cancer; 2004 Dec; 40(18):2837-44. PubMed ID: 15571968
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.
Traish AM; Morgentaler A
Br J Cancer; 2009 Dec; 101(12):1949-56. PubMed ID: 19888222
[TBL] [Abstract][Full Text] [Related]
12. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
13. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM; Almaraz-Pro C; Rodríguez-Ubreva FJ; Cortés MA; Ropero S; Colomer R; López-Ruiz P; Colás B
Neoplasia; 2007 Aug; 9(8):614-24. PubMed ID: 17898861
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma.
Fox SB; Persad RA; Coleman N; Day CA; Silcocks PB; Collins CC
Br J Urol; 1994 Aug; 74(2):214-20. PubMed ID: 7921940
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease.
Shi Y; Brands FH; Chatterjee S; Feng AC; Groshen S; Schewe J; Lieskovsky G; Cote RJ
J Urol; 2001 Oct; 166(4):1514-9. PubMed ID: 11547123
[TBL] [Abstract][Full Text] [Related]
16. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
17. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Vicentini C; Festuccia C; Gravina GL; Angelucci A; Marronaro A; Bologna M
J Cancer Res Clin Oncol; 2003 Mar; 129(3):165-74. PubMed ID: 12712332
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
Marks RA; Zhang S; Montironi R; McCarthy RP; MacLennan GT; Lopez-Beltran A; Jiang Z; Zhou H; Zheng S; Davidson DD; Baldridge LA; Cheng L
Prostate; 2008 Jun; 68(9):919-23. PubMed ID: 18409189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
